A Distinct Immunological Signature in Late‐Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study

Growing evidence supports that LOMG has a distinct immune pathomechanism. Further prospective studies are warranted to confirm the utility of these proteins as biomarkers of LOMG, and the feasibility of using them for more precise therapeutic targets to improve patient outcomes. ANN NEUROL 2026;99:198-210.